Shopping Cart

Your shopping cart is currently empty

Baicalin

Name: Baicalin
Brand: TargetMol
SKU: T2775
Price: 31 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: Baicalein 7-O-β-D-glucuronide) Copy Product Info

🥰Excellent

Synonyms: Baicalein 7-O-β-D-glucuronide

Catalog No. T2775 Copy Product Info

Purity: 99.32%

🥰Excellent

Baicalin (Baicalein 7-O-β-D-glucuronide) is a prolyl endopeptidase inhibitor isolated from Scutellaria baicalensis that exhibits anti-inflammatory, antioxidant, antitumor, and antiviral activity. Baicalin can be used in research on inflammation, neurodegenerative diseases, tumors, and metabolic syndrome.

Cas No. 21967-41-9

Pack Size	Price	USA Stock	Global Stock
50 mg	$31	In Stock	In Stock
100 mg	$44	In Stock	In Stock
200 mg	$47	In Stock	In Stock
500 mg	$53	In Stock	In Stock
1 g	$77	In Stock	In Stock
2 g	$109	-	In Stock
5 g	$163	-	In Stock
1 mL x 10 mM (in DMSO)	$48	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.32%

Appearance:Solid

Color:White to Yellow

Resource Download

COA LCMS HNMR

Product Introduction

Baicalin AI Summary

Baicalin exhibits a diverse range of biological activities. It displays binding affinity to the benzodiazepine site in the GABAA receptor with a Ki value of 77624.71 nM and shows inhibitory activity against bovine testis hyaluronidase with various IC50 values ranging from 450,000.0 nM to 1,600,000.0 nM. It has antiviral activity against HIV1 3B in human H9 cells with an EC50 of 112000.0 nM and demonstrates cytotoxicity with an IC50 of 72000.0 nM. The compound also inhibits trypsin-induced elevation in PAI1 production in HUVEC cells with an IC50 greater than 1,000,000.0 nM and reduces concanavalin A-induced histamine release in Wistar rat peritoneal mast cells with an ID50 of 3.0 x 10^-6 M. Baicalin shows weak displacement of [3H]LSD from the human 5HT7 receptor with an IC50 above 200,000.0 nM, and activity against SARS-CoV-2 3CL-Pro protease by 50.66% at 20 µM. The compound has antibacterial, antifungal, and antiviral activities, including activity against Chikungunya virus and SARS-CoV-2 with varying efficacies. It shows hepatoprotective, anti-inflammatory, cytotoxic, and anti-proliferative properties in different model systems and cell lines. Additionally, Baicalin exhibits activity as an inhibitor of LSD1 with an IC50 of 3010.0 nM and antiproliferative activity against human MGC-803 cells with an IC50 of 8780.0 nM. It affects various biological processes, including cell cycle regulation, enzyme inhibition, and immunomodulation. The compound also has potential for modulating DNA interactions, particularly G4 quadruplex and i-motif structures, and demonstrates permeability across biological barriers..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Baicalin (Baicalein 7-O-β-D-glucuronide) is a prolyl endopeptidase inhibitor isolated from Scutellaria baicalensis that exhibits anti-inflammatory, antioxidant, antitumor, and antiviral activity. Baicalin can be used in research on inflammation, neurodegenerative diseases, tumors, and metabolic syndrome.
In vitro	Methods: RAW264.7 cells were treated with baicalin (12.5, 25, 50 μM) for 24 hours. Surface CD14 and TLR4 proteins were detected by flow cytometry, and CD14 mRNA was detected by RT-qPCR. Results: Baicalin dose-dependently inhibited CD14 protein and mRNA expression without affecting TLR4 expression. [1]
In vivo	Methods: C57BL/6 mice were established with ulcerative colitis (UC) by free access to a 3% DSS solution for 5 days. Following modeling, Baicalin (100 mg/kg) was administered orally via gavage once daily for 5 consecutive days. Results: Baicalin treatment restored colon length, reduced spleen index, alleviated ulcer severity, and significantly suppressed CD14 and IL-6 expression in colonic mucosa. [1] Methods: Adult male SD rats received continuous oral administration of Baicalin (20, 60, 120 mg/kg) once daily for two weeks prior to surgery. Following drug administration, the left anterior descending artery (LAD) was ligated for 45 minutes, followed by reperfusion for 180 minutes to establish an MI/RI model. Results: I/R significantly impaired cardiac function. Baicalin at 60 and 120 mg/kg significantly improved HR, LVSP, LVFS, and LVEF in a dose-dependent manner. [2]
Synonyms	Baicalein 7-O-β-D-glucuronide

Chemical Properties

Molecular Weight	446.36
Formula	C₂₁H₁₈O₁₁
Cas No.	21967-41-9
Smiles	OC1=C2C(OC(=CC2=O)C3=CC=CC=C3)=CC(O[C@@H]4O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]4O)=C1O
Relative Density.	1.737 g/cm3

Storage & Solubility Information

Storage

Keep away from direct sunlight,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 37 mg/mL (82.89 mM), Sonication is recommended.

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

H2O: < 1 mg/mL (insoluble or slightly soluble)

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.96 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2403 mL	11.2017 mL	22.4034 mL	112.0172 mL
5 mM	0.4481 mL	2.2403 mL	4.4807 mL	22.4034 mL
10 mM	0.2240 mL	1.1202 mL	2.2403 mL	11.2017 mL
20 mM	0.1120 mL	0.5601 mL	1.1202 mL	5.6009 mL
50 mM	0.0448 mL	0.2240 mL	0.4481 mL	2.2403 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.